John G.F. Cleland
National Institutes of Health
1299 Papers
11.2K Citations
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 137, co-authored 1172 publications. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Chat about Author
Papers
Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF
Joost C. Beusekamp,Jasper Tromp,Haye H. van der Wal,Stefan D. Anker,Stefan D. Anker,John G.F. Cleland,Kenneth Dickstein,Kenneth Dickstein,Gerasimos Filippatos,Pim van der Harst,Hans L. Hillege,Chim C. Lang,Marco Metra,Leong L. Ng,Piotr Ponikowski,Nilesh J. Samani,Dirk J. van Veldhuisen,Aeilko H. Zwinderman,Patrick Rossignol,Faiez Zannad,Adriaan A. Voors,Peter van der Meer +21 more
TL;DR: The association between potassium and uptitration of angiotensin‐converting enzyme inhibitors (ACEi)/angiotens in receptor blockers (ARB) and its association with outcome was investigated.
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
John R. Teerlink,John J.V. McMurray,Robert C. Bourge,John G.F. Cleland,Gadi Cotter,Guillaume Jondeau,Henry Krum,Marco Metra,Christopher M. O'Connor,John D. Parker,Guillermo Torre-Amione,Dirk J. van Veldhuisen,Aline Frey,Maurizio Rainisio,Isaac Kobrin +14 more
TL;DR: The VERITAS program as mentioned in this paper was designed to enroll at least 1760 patients hospitalized with dyspnea at rest because of acute heart failure requiring intravenous therapy, and patients were randomized to receive tezosentan (5 mg/h for 30 minutes, then 1 mg /h for 24-72 hours) or matching placebo.
63
Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure: Results From COMET
Willem J. Remme,Christian Torp-Pedersen,John G.F. Cleland,Philip A. Poole-Wilson,Marco Metra,Michel Komajda,Karl Swedberg,Andrea Di Lenarda,Phillip Spark,Armin Scherhag,Christine Moullet,Mary Ann Lukas +11 more
TL;DR: In this article, the authors explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprololine European Trial) study.
62
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study
John G.F. Cleland,Kristian Thygesen,Barry F. Uretsky,Paul W. Armstrong,John D. Horowitz,B.M. Massie,Milton Packer,P. A. Poole-Wilson +7 more
TL;DR: A reduction in vascular events, as well as benefits on ventricular remodelling, could account for the decrease in death or hospitalization with high-dose lisinopril.
62
Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure
Michael M. Givertz,Douwe Postmus,Hans L. Hillege,George A. Mansoor,Barry M. Massie,Beth A. Davison,Piotr Ponikowski,Marco Metra,John R. Teerlink,John G.F. Cleland,Howard C. Dittrich,Christopher M. O'Connor,Gad Cotter,Adriaan A. Voors +13 more
TL;DR: Patients with acute heart failure and renal dysfunction demonstrate variable rise and fall in renal indices during and immediately after hospitalization, and risk of morbidity and mortality can be predicted based on baseline renal function and creatinine trajectory during the first 7 days.
62